24 citations
,
August 2009 in “Expert opinion on pharmacotherapy” The combination of calcipotriene and betamethasone is more effective and has fewer side effects for treating psoriasis.
6 citations
,
December 2018 in “Ophthalmic Plastic and Reconstructive Surgery” Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.
April 2023 in “Journal of The American Academy of Dermatology” Some drugs linked to growth hormones may increase the chance of hair loss in women.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
The 7.5% talok and 2% pare leaf extract hair tonic effectively promotes hair growth, similar to minoxidil.
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
146 citations
,
July 2003 in “Journal of the American Academy of Dermatology” Clobetasol propionate ointment can help some people with total hair loss regrow hair.
23 citations
,
September 2019 in “Journal of The American Academy of Dermatology” Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
December 2025 in “Orvosi Hetilap” Baricitinib is effective and safe for treating alopecia areata.
2 citations
,
January 2023 in “BioMed Research International” Beetroot extract nanogel may help treat hair loss caused by testosterone.
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
February 2026 in “JAAD International”
10 citations
,
January 2008 in “Biological and Pharmaceutical Bulletin” t-Flavanone may help hair growth by reducing a specific protein's activity in skin cells.
September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
40 citations
,
July 2023 in “Clinical Pharmacology & Therapeutics” Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
87 citations
,
March 2013 in “Expert Review of Anticancer Therapy” Afatinib often causes skin problems that need proactive management.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
June 2026 in “Eurasian Journal of Medicine”
July 2022 in “SKIN The Journal of Cutaneous Medicine” A new lotion with halobetasol and tazarotene successfully treats acne keloidalis nuchae.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
February 2023 in “Materials today bio” The treatment effectively promotes hair regrowth in androgenetic alopecia without causing skin irritation.
10 citations
,
July 2019 in “Indian Journal of Dermatology” Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.
Baricitinib is more effective than methotrexate for severe alopecia areata.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.